Fujimoto A, Hiramoto N, Yamasaki S, Inamoto Y, Uchida N, Maeda T, Mori T, Kanda Y, Kondo T, Shiratori S, et al. Risk factors and predictive scoring system for post-transplant lymphoproliferative disorder after hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2019;25(7):1441–9.

Article  Google Scholar 

Romero S, Montoro J, Guinot M, Almenar L, Andreu R, Balaguer A, Beneyto I, Espi J, Gomez-Codina J, Iacoboni G, et al. Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation. Leuk Lymphoma. 2019;60(1):142–50.

Article  PubMed  Google Scholar 

Styczynski J, Gil L, Tridello G, Ljungman P, Donnelly JP, van der Velden W, Omar H, Martino R, Halkes C, Faraci M, et al. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clin Infect Dis. 2013;57(6):794–802.

Article  PubMed  CAS  Google Scholar 

Dierickx D, Habermann TM. Post-transplantation lymphoproliferative disorders in adults. N Engl J Med. 2018;378(6):549–62.

Article  PubMed  CAS  Google Scholar 

Ibrahim HA, Naresh KN. Posttransplant lymphoproliferative disorders. Adv Hematol. 2012;2012: 230173.

Article  PubMed  PubMed Central  Google Scholar 

Curtis RE, Travis LB, Rowlings PA, Socie G, Kingma DW, Banks PM, Jaffe ES, Sale GE, Horowitz MM, Witherspoon RP, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999;94(7):2208–16.

PubMed  CAS  Google Scholar 

Tsushima T, Masuda SI, Yoda N, Kainuma S, Kimeda C, Konno S, Tanaka K, Matsuo K, Shimoji S, Kimura K, et al. Clinical characteristics and outcomes of Epstein–Barr virus viral load after allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2024;103(3):935–46.

Article  PubMed  CAS  Google Scholar 

Xu LP, Zhang CL, Mo XD, Zhang XH, Chen H, Han W, Chen YH, Wang Y, Yan CH, Wang JZ, et al. Epstein–Barr virus-related post-transplantation lymphoproliferative disorder after unmanipulated human leukocyte antigen haploidentical hematopoietic stem cell transplantation: incidence, risk factors, treatment, and clinical outcomes. Biol Blood Marrow Transpl. 2015;21(12):2185–91.

Article  Google Scholar 

Dharnidharka VR, Webster AC, Martinez OM, Preiksaitis JK, Leblond V, Choquet S. Post-transplant lymphoproliferative disorders. Nat Rev Dis Primers. 2016;2:15088.

Article  PubMed  Google Scholar 

Amengual JE, Pro B. How I treat posttransplant lymphoproliferative disorder. Blood. 2023;142(17):1426–37.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Styczynski J, Reusser P, Einsele H, de la Camara R, Cordonnier C, Ward KN, Ljungman P, Engelhard D. Second European Conference on Infections in L: management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transpl. 2009;43(10):757–70.

Article  CAS  Google Scholar 

Rouce RH, Louis CU, Heslop HE. Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant. Curr Opin Hematol. 2014;21(6):476–81.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lindsay J, Yong MK, Greenwood M, Kong DCM, Chen SCA, Rawlinson W, Slavin M. Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation. Rev Med Virol. 2020;30(4): e2108.

Article  PubMed  CAS  Google Scholar 

Landgren O, Gilbert ES, Rizzo JD, Socie G, Banks PM, Sobocinski KA, Horowitz MM, Jaffe ES, Kingma DW, Travis LB, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood. 2009;113(20):4992–5001.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Al Hamed R, Bazarbachi AH, Mohty M. Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities. Bone Marrow Transpl. 2020;55(1):25–39.

Article  CAS  Google Scholar 

Styczynski J, van der Velden W, Fox CP, Engelhard D, de la Camara R, Cordonnier C, Ljungman P. Sixth European Conference on Infections in Leukemia ajvotIDWPotESoB, Marrow Transplantation tIDGotEOfR, Treatment of Cancer tIIHS et al: Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica. 2016;101(7):803–11.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Garcia-Cadenas I, Yanez L, Jarque I, Martino R, Perez-Simon JA, Valcarcel D, Sanz J, Bermudez A, Munoz C, Calderon-Cabrera C, et al. Frequency, characteristics, and outcome of PTLD after allo-SCT: a multicenter study from the Spanish group of blood and marrow transplantation (GETH). Eur J Haematol. 2019;102(6):465–71.

Article  PubMed  CAS  Google Scholar 

Kinzel M, Dowhan M, Kalra A, Williamson TS, Dabas R, Jamani K, Chaudhry A, Shafey M, Jimenez-Zepeda V, Duggan P, et al. Risk factors for the incidence of and the mortality due to post-transplant lymphoproliferative disorder after hematopoietic cell transplantation. Transplant Cell Ther. 2022;28(1):53.

Article  Google Scholar 

O’Reilly M, Peggs KS. Off-the-shelf EBV-specific T-cell Immunotherapy for EBV-associated PTLD. Transplantation. 2020;104(10):1972–3.

Article  PubMed  CAS  Google Scholar 

Burns DM, Ryan GB, Harvey CM, Nagy E, Hughes S, Murray PG, Russell NH, Fox CP, Long HM. Non-uniform in vivo expansion of Epstein-Barr virus-specific T-cells following donor lymphocyte infusion for post-transplant lymphoproliferative disease. Front Immunol. 2019;10:2489.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Doubrovina E, Oflaz-Sozmen B, Prockop SE, Kernan NA, Abramson S, Teruya-Feldstein J, Hedvat C, Chou JF, Heller G, Barker JN, et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood. 2012;119(11):2644–56.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Pagliuca S, Schmid C, Santoro N, Simonetta F, Battipaglia G, Guillaume T, Greco R, Onida F, Sanchez-Ortega I, Yakoub-Agha I, et al. Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT. Lancet Haematol. 2024;11(6):e448–58.

Article  PubMed  CAS  Google Scholar 

Xu LP, Liu DH, Liu KY, Chen H, Han W, Wang Y, Wang J, Shi HX, Huang XJ. The efficacy and safety of donor lymphocyte infusion to treat Epstein-Barr virus associated lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation. Zhonghua Nei Ke Za Zhi. 2010;49(11):955–8.

PubMed  Google Scholar 

Lv M, Chang YJ, Huang XJ. Update of the “Beijing Protocol” haplo-identical hematopoietic stem cell transplantation. Bone Marrow Transpl. 2019;54(Suppl 2):703–7.

Article  CAS  Google Scholar 

Wang J, Zhao J, Fei X, Yin Y, Cheng H, Zhang W, Gu J, Yang F, Yang Y, Xue S, et al. A new intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia. Medicine (Baltimore). 2018;97(17): e0228.

Article  PubMed  Google Scholar 

Liu H, Zheng X, Zhang C, Xie J, Gao B, Shao J, Yang Y, Wang H, Yan J. Outcomes of haploidentical bone marrow transplantation in patients with severe aplastic anemia-II that progressed from non-severe acquired aplastic anemia. Front Med. 2021;15(5):718–27.

Article  PubMed  Google Scholar 

Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–86.

Article  PubMed  Google Scholar 

Martinez OM, Krams SM. The immune response to Epstein Barr virus and implications for posttransplant lymphoproliferative disorder. Transplantation. 2017;101(9):2009–16.

Article  PubMed  PubMed Central  Google Scholar 

Uygun V, Karasu G, Daloglu H, Ozturkmen S, Yalcin K, Celen SS, Yesilipek A. Use of low cell dose for unmanipulated donor lymphocyte for management of cytomegalovirus infection: a single-center experience. Pediatr Transpl. 2020;24(8): e13882.

Article  CAS  Google Scholar 

Taniguchi K, Yoshihara S, Tamaki H, Fujimoto T, Ikegame K, Kaida K, Nakata J, Inoue T, Kato R, Fujioka T, et al. Incidence and treatment strategy for disseminated adenovirus disease after haploidentical stem cell transplantation. Ann Hematol. 2012;91(8):1305–12.

Article  PubMed  CAS